| | 资金占用方 | 占用方与上市公 | 上市公司核算 | 2024 年期初 | 2024 年半年度占 | 2024 年半年度 | 2024 年半年度 | 2024 年半年度 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | | | | 用累计发生金额 | 占用资金的利息 | 偿还累计发生 | 期末占用资金 | | 占用性质 | | | 名称 | 司的关联关系 | 的会计科目 | 占用资金余额 | | | | | 原因 | | | | | | | | （不含利息） | （如有） | 金额 | 余额 | | | | 控股股东、实际控制人及 其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 其他关联方及其附属企业 | ...

一、担保情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"、"公 司"）于2023 年 10 月 27日召开第十届董事会第四次会议、2023年11月13日召开 2023年第四次临时股东大会审议通过了《关于公司及控股子公司担保额度预计的 议案》，同意公司为合并报表范围内子公司提供担保、子公司互相担保额度总计 不超过人民币 60,000 万元，并授权公司总经理在上述担保额度范围内，根据公 司及子公司实际日常经营资金需求办理担保事宜并签署相关文件，授权有效期 限与具体担保协议约定的保证期间一致，适用期限自股东大会审议通过之日起 至2024年12月31日止。 近日，公司全资子公司杭州贝瑞和康基因诊断技术有限公司（以下简称 "杭州贝瑞"）向杭州联合农村商业银行股份有限公司高沙支行申请综合授信 5,000万元，授信期限1年。为保证在上述授信额度内的全部债权能够得到清偿， 公司需为杭州贝瑞使用上述授信所形成的所有债务提供连带责任保证担保并签 署《最高额保证合同》（以下简称"本次担保"）。此外，公司控股股东高扬先 生为该笔授信提供个人连带责任保证担保。 成都市贝瑞和康基因技术股份有限公司 关于为控股子公司提供 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 551,776,302.07, a decrease of 1.59% compared to CNY 560,696,060.91 in the same period last year[10]. - Net profit attributable to shareholders was CNY 9,262,843.84, a significant increase of 109.74% from a loss of CNY 95,107,757.01 in the previous year[10]. - The net profit after deducting non-recurring gains and losses reached CNY 9,489,955.97, up 111.59% from a loss of CNY 81,863,981.19 in the same period last year[10]. - The net cash flow from operating activities was CNY 13,195,640.30, a remarkable increase of 317.05% compared to a negative cash flow of CNY 6,079,577.63 in the previous year[10]. - Basic and diluted earnings per share were both CNY 0.0262, recovering from a loss of CNY 0.269 per share in the same period last year, marking a 109.74% improvement[10]. - The total assets at the end of the reporting period were CNY 2,902,617,652.42, reflecting a growth of 5.89% from CNY 2,741,165,147.34 at the end of the previous year[10]. - The net assets attributable to shareholders increased to CNY 1,873,871,204.61, a slight rise of 0.53% from CNY 1,864,035,046.79 at the end of the previous year[10]. - The company achieved total revenue of ¥551,776,302.07, a decrease of 1.59% compared to the same period last year[28]. - Revenue from medical testing services was ¥199,449,499.48, a decrease of 10.88% year-on-year[28]. - Revenue from reagent sales increased by 21.29% to ¥257,599,110.45[28]. - Revenue from equipment sales decreased by 29.39% to ¥17,045,915.08[28]. - The company achieved a significant reduction in operating costs, which fell by 16.88% to ¥263,774,077.25[31]. - The gross margin for the genetic testing industry improved by 8.80% to 52.20% despite a slight decline in revenue[33]. - The company reported a net profit contribution of -¥448.96 million from the sale of assets, which accounted for 35.60% of total net profit[42]. Business Operations - The main business focus is on high-throughput sequencing technology-based genetic testing services, including sales of related equipment and reagents[15]. - The company offers a comprehensive range of genetic testing services, including non-invasive prenatal testing (NIPT) for chromosomal abnormalities and single-gene disorders, covering 153 diseases[15]. - The "贝比安 Plus" NIPT service screens for 17 types of fetal chromosomal abnormalities and 76 types of microdeletion syndromes, enhancing prenatal diagnostic capabilities[16]. - The company utilizes third-generation sequencing technology for various genetic tests, including screening for thalassemia and spinal muscular atrophy, improving diagnostic accuracy[16]. - The "贝新安" newborn genetic screening covers 103 genetic diseases, identifying pathogenic or potentially pathogenic variants in 358 target genes[16]. - The company is committed to the clinical application of genetic sequencing technology, focusing on reproductive health, genetic disease testing, and tumor detection[15]. - The company aims to expand its market presence by providing integrated "product + service" solutions to hospitals and research institutions[15]. - The company is actively developing new products and technologies to enhance its service offerings in the genetic testing market[15]. - The company has launched the world's first clinical-level liver cancer early screening product "Lai Si Ning," validated by a prospective cohort study involving over 10,000 participants[17]. - The multi-cancer early screening product "Quan Si Ning" can screen for six major high-risk cancers in China, utilizing cfDNA multi-dimensional whole genome sequencing technology[17]. - The company has established a comprehensive range of sequencing analysis services, leveraging platforms like Illumina NovaSeq X Plus and PacBio Revio, covering various research fields including tumor and genetic disease studies[18]. - The company’s NIPT library preparation reagents utilize the proprietary EZ-PALO rapid library preparation method, enhancing efficiency and simplicity[19]. - The NextSeq CN500 platform has been adopted by over 200 qualified medical institutions and third-party testing organizations for large-scale clinical genetic testing[21]. - The Sequel® II CNDx platform is currently in the medical device registration phase, aimed at detecting complex single-gene diseases, particularly thalassemia[21]. - The NovaSeqTM 6000Dx-CN-BG platform is also in the medical device registration phase, designed for whole genome sequencing (WGS) and whole exome sequencing (WES) applications[21]. - The company offers a variety of reagents, including NIPT DNA extraction and purification reagents, which are characterized by their rapid and efficient performance[20]. - The company focuses on high-throughput second and third-generation sequencing hardware platforms to drive reagent sales in genetic and tumor fields[21]. - The company has developed a range of sequencing reagents in collaboration with Illumina, ensuring stable and accurate performance[20]. Market and Competitive Landscape - The company faces risks from intensified market competition and declining service prices, which could impact its market share and future performance[48]. - The company is at risk of technological and product innovation lag, which may lead to decreased market share and profit margins if it fails to keep pace with industry advancements[49]. - The company reported a potential risk of declining gross margins due to increased competition and regulatory uncertainties in the gene sequencing industry[50]. - Accounts receivable are increasing rapidly due to the company's business expansion, posing a risk of bad debts and potential liquidity issues[50]. - The company is focusing on new project development to address gaps in its testing product line, which may cause performance fluctuations[49]. - The company is actively managing risks associated with overseas operations, including compliance with international regulations and potential geopolitical impacts[50]. Governance and Compliance - The company received administrative regulatory measures from the China Securities Regulatory Commission due to internal control and accounting issues[61]. - The company has implemented a comprehensive internal control rectification plan, including enhancing procurement management and sales management processes[63]. - A third-party professional institution has been hired to comprehensively review and improve the company's internal control system[63]. - The company has established a special group for accounts receivable recovery, focusing on background checks and risk assessments for clients[62]. - The company has improved its internal reporting procedures to ensure timely feedback of significant information across departments[63]. - The company has completed initial rectification measures and will continue to enforce compliance with internal control standards[64]. - The company reported that the rectification activities have positively impacted its governance structure and operational transparency[64]. - The company has emphasized the importance of compliance training for its management and staff to enhance operational awareness and internal control supervision[65]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the first half of 2024[54]. - A total of 85 employees participated in the employee stock ownership plan, holding a total of 2,823,000 shares, which represents 0.80% of the company's total equity[55]. - The first phase of the employee stock ownership plan has been extended for an additional 12 months, now set to expire on March 31, 2025[56]. - The total number of shares before the recent changes was 353,521,465, with a decrease of 18,233,989 shares due to the release of restricted shares, resulting in a new total of 318,258,593 shares[80]. - The proportion of restricted shares decreased from 15.13% to 9.97% after the changes, while the proportion of unrestricted shares increased from 84.87% to 90.03%[79]. - The company’s management has reduced their locked shares by 18,233,989, resulting in a new total of 35,262,872 restricted shares[80]. - The total amount of related party transactions for the reporting period was 30.88 million, with no significant impact on the company's financial status or independence[67]. Future Outlook and Strategy - The company plans to continue focusing on market expansion and new product development to drive future growth[100]. - The company is exploring potential mergers and acquisitions to strengthen its market position[116]. - The future outlook remains cautious due to market volatility and competitive pressures[116]. - The company has set performance guidance for the next quarter, anticipating a modest recovery in revenue growth[116]. Accounting and Financial Reporting - The financial statements are prepared based on the historical cost principle, ensuring reliable measurement of accounting elements[121]. - The company has not reported any significant events affecting its ability to continue operations[122]. - The company has undergone significant asset restructuring, acquiring 100% equity of Beijing Beirui and Kang Biotechnology Co., Ltd.[119]. - The stock name changed from "*ST Tianyi" to "Beirui Gene" following the completion of the asset restructuring[120]. - The company’s financial reporting is influenced by the judgments made regarding the timing and progress of performance obligations[199].

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-048 成都市贝瑞和康基因技术股份有限公司 第十届监事会第六次会议决议公告 监事会审阅了《2024 年半年度报告全文及摘要》，认为其内容真实、准确、 完整，不存在任何的虚假记载、误导性陈述或者重大遗漏。 2、审议通过《关于向参股公司提供借款的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第六次会议于 2024 年 8 月 22 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场会议的方式召开，会议通知已于 2024 年 8 月 16 日以邮件形式发送 给各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事会 会议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生主 持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有关法 律、行政法规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-047 成都市贝瑞和康基因技术股份有限公司 关于向参股公司提供借款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 一、借款事项概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"或 "上市公司"）全资子公司福建贝瑞和康基因技术有限公司（以下简称"福建贝 瑞"）与福州滨海临空开发建设有限公司（以下简称"滨海开发"）合资设立的 福州新投生物科技产业园建设发展有限公司（以下简称"合资公司"）已于2024 年3月1日完成设立并投入运营，其中，滨海开发持有合资公司51%的股份，福建 贝瑞持有合资公司49%的股份，为满足合资公司开发建设运营资金需求，股东双 方拟对合资公司按持股比例提供借款。 合资公司股东双方拟于2024年10月31日前，按出资比例向其提供借款合计 3,000万元（其中滨海开发提供借款1,530万元，福建贝瑞提供借款1,470万元）， 借款期限为自实际提供借款之日起一年，借款利率按股东实际提供借款之日的一 年期LPR的140%计算。 本次借款不影响公司 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-045 成都市贝瑞和康基因技术股份有限公司 第十届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第十次会议于 2024 年 8 月 22 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2024 年 8 月 16 日以 邮件形式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。 本次董事会会议应出席董事 7 名，实际出席会议董事 7 名，会议由董事长高扬先 生主持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。 2、审议通过《关于向参股公司提供借款的议案》 表决结果：7 票同意，0 票反对，0 票弃权。 公司与福州滨海临空开发建设有限公司（以下简称"滨海开发"）合资设立 的福州新投生物科技产业园建设发展有限公司（以下简称"合资公司"）已于 20 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-041 成都市贝瑞和康基因技术股份有限公司 第十届董事会第九次会议决议公告 1、审议通过《关于聘任公司董事会秘书的议案》 表决结果：7 票同意，0 票反对，0 票弃权。 艾雯露女士因工作调整申请辞去董事会秘书职务，辞职后将在公司担任其他 职务。 公司董事会同意聘任公司投资者关系总监许菲先生担任公司董事会秘书职 务，履行董事会秘书职责，任期自董事会审议通过之日起至第十届董事会届满之 日，提名委员会对任职资格进行了审查（简历见附件）。具体内容详见公司在巨 潮资讯网披露的《关于聘任公司董事会秘书的公告》（公告编号 2024-042）。 三、备查文件 1、第十届董事会第九次会议决议 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第九次会议于 2024 年 7 月 24 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2024 年 7 月 19 日以 邮件形式发送给 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-043 成都市贝瑞和康基因技术股份有限公司 关于全资子公司出售资产进展暨完成产权过户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 成都市贝瑞和康基因技术股份有限公司董事会 2024年7月24日 二、 交易进展 近日，福州产业园过户手续已全部办理完毕，福建产业园已变更登记到合资 公司福州新投生物科技产业园建设发展有限公司名下，并取得《不动产权证书》。 三、 备查文件 《不动产权证书》 一、 交易概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"）分 别于2024年2月3日、2024年2月21日召开第十届董事会第六次会议、2024年第一 次临时股东大会，审议通过了《关于全资子公司对外投资成立合资公司的议案》、 《关于全资子公司出售资产的议案》等福州产业园交易相关议案。同意公司全资 子公司福建贝瑞和康基因技术有限公司（以下简称"福建贝瑞"）与福州滨海临 空开发建设有限公司共同成立合资公司福州新投生物科技产业园建设发展有限 公司（以下简称"福州新投"），由福州新 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-042 成都市贝瑞和康基因技术股份有限公司 关于聘任公司董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会秘书辞职情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）董事会于近日 收到公司董事会秘书艾雯露女士的辞职报告，艾雯露女士因工作调整申请辞去 董事会秘书职务，辞职后将在公司担任其他职务。截至本公告日，艾雯露女士 未直接持有公司股份。根据《深圳证券交易所上市公司自律监管指引第1号—— 主板上市公司规范运作》等相关规定，艾雯露女士的辞职报告自送达公司董事 会时生效。艾雯露女士在担任公司董事会秘书期间恪尽职守、勤勉尽责，公司 和董事会对艾雯露女士在任职期间为公司发展所做的贡献表示衷心感谢！ 成都市贝瑞和康基因技术股份有限公司董事会 2024年7月24日 附件： 许菲先生简历 许菲先生，1986 年出生，中国国籍，本科学历，无境外永久居留权。许菲先 生 2012 年 5 月至 2024 年 6 月任职于北京数字政通科技股份有限公司，担任监 事、证券事务代表，现任公司 ...

暨股东持股比例变动超过1%的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 控股股东之一致行动人侯颖女士保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 公司于近日通过中国证券登记结算有限责任公司深圳分公司（以下简称"中登结 算公司"）系统查询，获悉公司控股股东之一致行动人侯颖女士被司法拍卖的 5,284,925 股股票已完成过户登记手续，现将有关情况公告如下： 证券代码：000710 证券简称：贝瑞基因 公告编号：2024-040 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人被司法拍卖的股份完成过户 1．基本情况 一、 本次司法拍卖的基本情况 成渝金融法院于 2024 年 7 月 15 日 10：00 时起至 2024 年 7 月 16 日 10：00 时 止在淘宝网司法拍卖网络平台公开拍卖公司控股股东之一致行动人侯颖女士持有的 公司 5,284,925 股股票，根据拍卖平台公示的《网络竞价成功确认书》，竞买人王 俊、王灯城竞拍成功，详 ...